Balkan endemic nephropathy (BEN) is a familial chronic tubulointerstitial disease with insidious onset and slow progression to terminal renal failure. Evidence has accumulated that BEN is an environmentally induced disease. There are three actual theories attempting to explain the environmental cause of this disease: (1) the aristolochic acid hypothesis, which considers that the disease is produced by chronic intoxication with Aristolochia, (2) the mycotoxin hypothesis, which considers that BEN is produced by ochratoxin A, and (3) the Pliocene lignite hypothesis, which proposes that the disease is caused by long-term exposure to polycyclic aromatic hydrocarbons and other toxic organic compounds leaching into the well drinking water from low-rank coals in the vicinity to the endemic settlements. Moreover, it was suggested that BEN risk is influenced by inherited susceptibility. Therefore, it has been expected that molecular biological investigations will discover genetic markers of BEN and associated urothelial cancer, permitting early identification of susceptible individuals who may be at risk of exposure to the environmental agents. Since kidney pathophysiology is complex, gene expression analysis and highly throughput proteomic technology can identify candidate genes, proteins and molecule networks that eventually could play a role in BEN development. Investigation of gene-gene and gene-environment interactions could be the content of further studies determining the precise risk for BEN.

Keywords:
Balkan endemic nephropathy, etiology, Balkan endemic nephropathy, genetic predisposition, Urothelial cancer, Xenobiotic-metabolizing genes, Aristolochic acid, Ochratoxin A, Polycyclic aromatic hydrocarbons
1.
Polenakovic M, Stefanovic V: Balkan Nephropathy; in Cameron JS, Davison AM, Grunfeld JP, Kerr D, Ritz E (eds): Oxford Textbook of Clinical Nephrology, ed 1. Oxford, Oxford University Press, 1992, pp 857–866.
2.
Stefanovic V: Balkan endemic nephropathy: a need for novel aetiological approaches. Q J Med 1998;91:457–463.
3.
Stefanovic V, Cosyns JP: Balkan Nephropathy; in Davison AM, Cameron JS, Grunfeld JP, Ponticelli C, Van Ypersele C, Ritz E, Winearls CG (eds): Oxford Textbook of Clinical Nephrology, ed 3. Oxford, Oxford University Press, 2004, pp 1095–1102.
4.
Cukuranovic R, Petrovic B, Cukuranovic Z, Stefanovic V: Balkan endemic nephropathy: a decreasing incidence of the disease. Pathol Biol 2000;48:558–561.
5.
Dimitrov PS, Simeonov VA, Ganev VS, Karmaus WJ: Is the incidence of Balkan endemic nephropathy decreasing? Pathol Biol 2002;50:38–41.
6.
Djukanovic L, Radovic M, Bakovic J, et al: Epidemiology of end-stage renal disease and current status of hemodialysis in Yugoslavia. Int J Artif Organs 2002;25:852–859.
7.
Petkovic S, Mutavdzic M, Petronic V, Markovic V: Les tumeurs du bassinet et de l’uretère. Recherches cliniques et étiologiques. J Urol Néphrol 1971;77:429–439.
8.
Chernozemsky IN, Stoyanov IS, Petkova-Bocharova TK, et al: Geographic correlation between the occurrence of endemic nephropathy and urinary tract tumours in Vratza district, Bulgaria. Int J Cancer 1977;19:1–11.
9.
Cukuranovic R, Ignjatovic M, Stefanovic V: Urinary tract tumors and Balkan nephropathy in the South Morava River basin. Kidney Int 1991;40(suppl 34):S80–S84.
10.
Markovic N, Ignjatovic I, Cukuranovic R, et al: Decreasing incidence of urothelial cancer in a Balkan endemic nephropathy region in Serbia. A surgery-based study from 1969 to 1998. Pathol Biol 2005;53:26–29.
11.
Toncheva D, Dimitrov T, Stojanova S: Etiology of Balkan endemic nephropathy: a multifactorial disease? Eur J Epidemiol 1998;14:389–394.
12.
Pavlovic NM, Vargheze Z, Persaud JW, et al: Partial lecithin:cholesterol acyltransferase deficiency in Balkan endemic nephropathy. Kidney Int 1991;40(suppl 34):S102–S105.
13.
Djordjevic VB, Strahinjic S, Koracevic D, et al: δ-Aminolevulinate dehydratase measurements in Balkan endemic nephropathy. Kidney Int 1991;40(suppl 34):S93–S96.
14.
Nikolov I, Chernozemsky I, Idle J: Genetic predisposition to Balkan endemic nephropathy: ability hydroxylate debrisoquine as a host factor; in Castegnaro M, Plestina R, Dirheimer G, Chernozemsky I, Bartasch H (eds): Mycotoxins, endemic nephropathy and urinary tract tumors. Lyon, IARC, 1991, pp 289–296.
15.
Atanasova SY, von Ahsen N, Toncheva DI, et al: Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy. Clin Biochem 2005;38:223–228.
16.
Toncheva D, von AhsenD, Atanasova S, et al:Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. J Nephrol 2004;17:384–389.
17.
Andonova R, Sarueva A, Horvath V, et al: Balkan endemic nephropathy and genetic variants of glutathione S-transferases. J Nephrol 2004;17:390–398.
18.
Atanasova S, von Ahsen N, Dimitrov T, et al: First study of NAT1 and NAT2 polymorphisms in Bulgarian patients with Balkan endemic nephropathy and healthy controls. Biotechnol Biotechnol Equip 2004;18:95–103.
19.
Zepnik H, Pahler A, Schauer U, Dekant W: Ochratoxin A-induced tumor formation: is there a role of reactive ochratoxin A metabolites? Toxicol Sci 2001;59:59–67.
20.
Perri D, Ito S, Rowsell V, Shear NH: The kidney – the body’s playground for drugs: an overview of renal drug handling with selected clinical correlates. Can J Clin Pharmacol 2003;10:17–23.
21.
Kim RB, Leake BF, Choo EF, et al: Identification of functionally variant MDR1 alleles among European-Americans and African-Americans. Clin Pharmacol Ther 2001;70:189–199.
22.
Atanasova S, von Ahsen N, Dimitrov T, et al: MDR1 haplotypes modify BEN disease risk: a study in Bulgarian patients with Balkan endemic nephropathy compared to healthy controls. Nephron Exp Nephrol 2004;96:e7–e13.
23.
Klahr S: Progression of chronic renal disease. Heart Dis 2001;3:205–209.
24.
Pelletier R, Pravica V, Perrey C, et al: Evidence for a genetic predisposition towards acute rejection after kidney and simultaneous kidney-pancreas transplantation. Transplantation 2000;70:674–680.
25.
Lacha J, Hubacek JA, Potmesil P, et al: TGF-β1 gene polymorphism in heart transplant recipients – effect on renal function. Ann Transplant 2001;6:39–43.
26.
Atanasova S, von Ahsen N, Dimitrov T, et al: Real-time polymerase chain reaction for genotyping of the transforming grow factor-β1 polymorphism Thr263Ile in patients with Balkan endemic nephrology and in healthy Bulgarian population. Balkan J Med Genet 2002;5:37–41.
27.
Cambien F, Ricard S, Troesch A, et al: Polymorphisms of the transforming growth factor-β1 gene in relation to myocardial infarction and blood pressure. Hypertension 1996;28:881–887.
28.
Toncheva DI, Gerov TD, Tzoneva MT, Bouchakliev ZP: Spontaneous and induced chromosome aberrations in Balkan endemic nephropathy. Kidney Int 1991;40(suppl 34):S97–S101.
29.
Toncheva D, Dimitrov T, Tzoneva M: Cytogenetic studies in Balkan endemic nephropathy. Nephron 1988;48:18–21.
30.
Toncheva D, Dimitrov T: Genetic predisposition to Balkan endemic nephropathy. Nephron 1996;72:564–569.
31.
Toncheva D, Atanassova S, Gergov T, et al: Genetic changes in uroepithelial tumors of patients with Balkan endemic nephropathy. J Nephrol 2002;15:387–393.
32.
Danilovic V, Djurisic M, Mokranjac M, et al: Néphrites chroniques provoquées par l’intoxication au plomb par voie digestive (farine). Presse Méd 1957;65:2039–2040.
33.
Maksimovic ZJ: Selenium deficiency and Balkan endemic nephropathy. Kidney Int 1991;40(suppl 34):S12–S14.
34.
Cukuranovic R, Nikolic J, Stefanovic V: Erythrocyte glutathione peroxidase activity in patients with Balkan endemic nephropathy and in their healthy family members. Arch Biol Sci 1992;44:23–30.
35.
Stefanovic V, Cukuranovic R, Mitic-Zlatkovic M, Hall PW: Increased urinary albumin excretion in children from families with Balkan nephropathy. Pediatr Nephrol 2002;17:913–916.
36.
Stefanovic V, Mitic-Zlatkovic M, Cukuranovic R, Vlahovic P: Increased urinary protein excretion in children from families with Balkan endemic nephropathy. Nephron Clin Pract 2003;95:C116–C120.
37.
Ivić M: The problem of etiology of endemic nephropathy. Acta Fac Med Naiss 1970;1:29–37.
38.
Hranjec T, Kovac A, Kos J, et al: Endemic nephropathy: the case for chronic poisoning by Aristolochia. Croat Med J 2005;46:116–125.
39.
Vanherweghem JL, Depierreux M, Tielmans C, et al: Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387–391.
40.
Cosyns JP, Jadoul M, Squifflet JP, et al: Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? Kidney Int 1994;45:1680–1688.
41.
Cosyns JP, Jadoul M, Squifflet JP, et al: Urothelial lesions in Chinese herb nephropathy. Am J Kidney Dis 1999;33:1011–1017.
42.
Nortier JL, Muniz MC, Schmeiser HH, et al: Urothelial carcinoma associated with the use of a Chinese herbs (Aristolochia species). N Engl J Med 2000;342:1686–1692.
43.
Stefanovic V: Analgesic nephropathy, Balkan endemic nephropathy and Chinese herbs nephropathy: separate tubulointerstitial kidney diseases associated with urothelial malignancy. Facta Universitatis 2002;9:1–6.
44.
Vanherweghem JL, Abramowicz D, Tielemans C, Depierreux M: Effects of steroids on the progression of renal failure in chronic interstitial renal fibrosis: a pilot study in Chinese herbs nephropathy. Am J Kidney Dis 1996;27:209–215.
45.
Arlt VM, Stiborova M, Schmeiser HH: Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002;17:265–277.
46.
Schmeiser HH, Bieler CA, Wiessler M, et al: Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 1996;56:2025–2028.
47.
Arlt VM, Pfohl-Leszkowicz A, Cosyns JP, Schmeiser HH: Analyses of DNA adducts formed by ochratoxin A and aristolochic acid in patients with Chinese herbs nephropathy. Mutat Res 2001;494:143–150.
48.
Arlt VM, Wiessler M, Schmeiser HH: Using polymerase arrest to detect DNA binding specificity of aristolochic acid in the mouse H-ras gene. Carcinogenesis 2000;21:235–242.
49.
Lord GM, Hollstein M, Arlt VM, et al: DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am J Kidney Dis 2004;43:e11–e17.
50.
Cosyns JP, Dehoux JP, Guiot Y, et al: Chronic aristolochic acid toxicity in rabbits: a model of Chinese herbs nephropathy? Kidney Int 2001;59:2164–2173.
51.
Debelle FD, Nortier JL, de Prez EG, et al: Aristolochic acids induce chronic renal failure with interstitial fibrosis in salt-depleted rats. J Am Soc Nephrol 2002;13:431–436.
52.
Arlt VM, Ferluga D, Stiborova M, et al: Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? Int J Cancer 2002;101:500–502.
53.
Krogh P, Axelsen NH, Elling F, et al: Experimental porcine nephropathy. Changes of renal function and structure induced by ochratoxin-A-contaminated food. Acta Pathol Microbiol Scand [A] 1974;246(suppl):1–24.
54.
Krogh P, Hald B, Pleština R, Čeović S: Balkan (endemic) nephropathy and foodborne ochratoxin A: preliminary results of a survey of foodstuffs. Acta Pathol Microbiol Scand, B Microbiol 1977;85:238–240.
55.
Pfohl-Leszkowicz A, Grosse Y, Kane A, et al: Differential DNA adduct formation and disappearance in three mouse tissues after treatment with the mycotoxin ochratoxin A. Mutat Res 1993;289:265–273.
56.
Pfohl-Leszkowicz A, Grosse Y, Castegnaro M, et al: Ochratoxin A related DNA adducts in urinary tract tumours of Bulgarian subjects. IARC Sci Publ 1993;124:141–148.
57.
Mantle PG: Experimental mycotoxic nephropathies and Balkan endemic nephropathy. Facta Universitatis 2002;9:64–65.
58.
Savin M, Bumbasirevic V, Djukanovic L, Petronic V: The significance of apoptosis for early diagnosis of Balkan nephropathy. Nephrol Dial Transplant 2001;16(suppl 6):S30–S32.
59.
Feder GL, Radovanović Z, Finkelman RB: Relationship between weathered coal deposits and the aetiology of Balkan endemic nephropathy. Kidney Int 1991;40(suppl 34):S9–S11.
60.
Goldberg MC, Feder GL, Radovanovic Z: Correlation of Balkan endemic nephropathy with fluorescent organic compounds in shallow ground water. Appl Hydrogeol 1994;2:15–23.
61.
Voice TC, McElmurry SP, Long DT, et al: Evaluation of coal leachate contamination of water supplies as a hypothesis for the occurrence of Balkan endemic nephropathy in Bulgaria. Facta Universitatis 2002;9:128–129.
62.
Niagolova N, McEllmurry SP, Voice TC, et al: Nitrogen species in drinking water indicate potential exposure pathway for Balkan endemic nephropathy. Envir Pollut 2005;134:229–237.
63.
Apostolov K, Spasic P, Bojanic N: Evidence of a viral aetiology in endemic (Balkan) nephropathy. Lancet 1975;ii:1271–1273.
64.
Uzelac-Keserovic B, Spasic P, Bojanic N, et al: Isolation of a coronavirus from kidney biopsies of endemic Balkan nephropathy patients. Nephron 1999;81:141–145.
65.
Riquelme C, Escors D, Ortego J, et al: Nature of the virus associated with endemic Balkan nephropathy. Emerg Infect Dis 2002;8:869–870.
66.
Toncheva D, Galabov AS, Laich A, et al: Urinary neopterin concentrations in patients with Balkan endemic nephropathy. Kidney Int 2003;64:1817–1821.
67.
Tourraine JL, Malik MC, Stefanovic V, et al: Lack of recurrence of endemic nephropathy over the first five years following renal transplantation. Abstr 8th Int Congr Nephrol, Athens, 1981, p 487.
68.
Reginster F, Jadoul M, van Ypersele de Strihou C: Chinese herbs nephropathy presentation, natural history and fate after transplantation. Nephrol Dial Transplant 1997;12:81–86.
69.
Stefanovic V, Polenakovic M: Balkan nephropathy. Kidney disease beyond the Balkans? Am J Nephrol 1991;11:1–11.
70.
Cosyns JP: Aristolochic acid and ‘Chinese herbs nephropathy’. A review of the evidence to date. Drug Saf 2003;26:33–48.
71.
Stefanovic V, Radenkovic S, Cukuranovic R, Kostic S: Balkan endemic nephropathy: avoidance of etiological factors arrests progression of kidney disease. Nephron 1999;83:85–86.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.